GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Lepu Biopharma Co 2157.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

2.97

+3.13%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥1.06bn

FY2019FY2025

Net income

CN¥296.4m

FY2019FY2025

Free cash flow

−CN¥96.4m

FY2019FY2025

Shareholders' equity

CN¥1.61bn

FY2019FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
RevenueCN¥1.06bnCN¥367.8mCN¥225.4mCN¥18.1m———
Gross profitCN¥852.2mCN¥293.0mCN¥197.1mCN¥15.8m−CN¥133.6m——
Research and developmentCN¥390.6mCN¥437.7mCN¥458.1mCN¥610.3mCN¥921.0mCN¥412.6mCN¥266.8m
Operating incomeCN¥101.8m−CN¥405.9mCN¥4.8m−CN¥820.0m−CN¥1.18bn−CN¥605.7m−CN¥529.2m
Net incomeCN¥296.4m−CN¥411.4m−CN¥22.1m−CN¥802.1m−CN¥1.18bn−CN¥677.3m−CN¥520.4m
Diluted earnings per share0.16-0.24-0.01-0.48-0.71-0.41-0.31

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Total assetsCN¥3.61bnCN¥2.28bnCN¥2.78bnCN¥2.94bnCN¥2.42bnCN¥2.82bnCN¥1.78bn
Cash and short-term investmentsCN¥1.12bnCN¥464.9mCN¥570.0mCN¥789.4mCN¥238.8mCN¥886.3mCN¥219.5m
Total liabilitiesCN¥2.00bnCN¥1.60bnCN¥1.74bnCN¥1.90bnCN¥1.44bnCN¥1.07bnCN¥1.99bn
DebtCN¥1.24bnCN¥840.2mCN¥741.8mCN¥683.6mCN¥331.1mCN¥199.3mCN¥574.7m
Shareholders' equityCN¥1.61bnCN¥702.8mCN¥1.04bnCN¥1.05bnCN¥973.9mCN¥1.72bn−CN¥410.3m
Shares outstanding1,805m1,711m1,659m1,659m1,659m1,659m1,659m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations−CN¥44.9m−CN¥196.4m−CN¥250.8m−CN¥559.8m−CN¥723.7m−CN¥492.0m−CN¥272.4m
Capital spending−CN¥51.5m−CN¥61.7m−CN¥41.2m−CN¥128.6m−CN¥248.4m−CN¥351.3m−CN¥370.7m
Free cash flow−CN¥96.4m−CN¥258.1m−CN¥292.0m−CN¥688.4m−CN¥972.1m−CN¥843.3m−CN¥643.1m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Sept 2024Jun 2024Mar 2024Dec 2023
RevenueCN¥599.7mCN¥536.7mCN¥542.4mCN¥234.5mCN¥136.5mCN¥133.4mCN¥77.6mCN¥71.6m
Gross profitCN¥486.5mCN¥412.3mCN¥510.5mCN¥180.7mCN¥105.2mCN¥112.4mCN¥65.4mCN¥49.1m
Operating incomeCN¥71.1mCN¥7.7mCN¥50.0m−CN¥206.7m−CN¥120.3m−CN¥184.2m−CN¥107.2mCN¥122.5m
Net incomeCN¥31.4mCN¥251.4mCN¥48.6m−CN¥218.9m−CN¥127.4m−CN¥192.6m−CN¥112.1mCN¥119.5m
Diluted earnings per share0.020.140.03-0.13-0.07-0.11-0.070.07
Cash from operations—−CN¥82.0mCN¥41.0m−CN¥81.0m—−CN¥115.0m−CN¥67.0m−CN¥203.0m
Capital spending—−CN¥15.0m−CN¥40.0m−CN¥20.0m—−CN¥12.0m−CN¥7.0m−CN¥11.0m
Free cash flow—−CN¥97.0mCN¥1.0m−CN¥101.0m—−CN¥127.0m−CN¥74.0m−CN¥214.0m
Total assetsCN¥3.68bnCN¥3.61bnCN¥2.75bnCN¥2.28bnCN¥2.65bnCN¥2.44bnCN¥2.84bnCN¥2.38bn
Cash and short-term investmentsCN¥918.2mCN¥1.12bnCN¥624.3mCN¥464.9mCN¥541.2mCN¥577.3mCN¥682.4mCN¥489.6m
DebtCN¥832.0mCN¥1.24bnCN¥1.07bnCN¥850.2mCN¥666.7mCN¥774.9mCN¥612.4mCN¥746.8m
Shareholders' equityCN¥1.64bnCN¥1.61bnCN¥867.5mCN¥702.8mCN¥818.1mCN¥914.8mCN¥1.06bnCN¥896.9m

Financial ratios

Data as of 9 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin80.4%79.7%87.5%87.1%——
Operating margin9.6%-107.6%-6.9%-4443.7%——
Net margin28.0%-111.8%-9.8%-4424.9%——
Return on equity18.4%-58.5%-2.5%-76.5%-120.8%-39.5%
Return on assets8.2%-18.0%-0.9%-27.2%-48.6%-24.0%
Free cash flow yield0.1%-2.1%-3.3%-5.8%-6.4%—
Revenue growth147.6%63.2%1347.2%———
Earnings growth-161.9%1761.8%-96.8%-31.8%73.8%30.2%
Current ratio0.98x0.62x0.75x0.96x0.57x2.21x
Debt to equity0.77x1.19x0.81x0.76x0.38x0.12x
Equity ratio44.7%30.8%37.6%35.6%40.2%60.8%
Interest coverage3.06x-18.28x-1.06x-92.67x-349.56x-5.25x
R&D as a share of sales36.8%119.0%203.3%3366.8%——
Buybacks as a share of market value-5.5%-3.1%-0.0%-0.1%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue288.2%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin80.2%81.3%——
Operating margin-21.3%-67.0%——
Net margin-8.1%-56.2%——

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022
Price to earnings26.4-9.4-273.9-13.2
Price to sales7.410.526.9—

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.